Sec. 761.
120 words·~1 min read·
/bill/118/hr/4368/rh/section-761A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The modifications made by the Food and Drug Administration on January 3, 2023 to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355-1 ) for mifepristone are hereby nullified. None of the funds made available by this Act may be used to establish, implement, or enforce— any provision of a risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355-1 ) for mifepristone that is substantially similar to any of the modifications nullified by subsection (a); or any non-enforcement or enforcement discretion policy for any provision of a risk evaluation and mitigation strategy under such section for mifepristone.
Connectionstraces to 1
Traces to 1 document